An open label study to evaluate the effect of PEGASYS [peginterferon alfa-2a] on ALT [alanine transminase] and HBV [hepatitis-B virus] DNA levels in patients with lamivudine-resistant HbeAg-negative chronic hepatitis B.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2010
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 30 Jun 2008 Status changed from recruiting to discontinued, as reported by Roche.
- 22 Oct 2007 Status changed from initiated to recruiting